About Bioduro
Bioduro is a Healthcare company based in San Diego (United States) founded in 2005, and was acquired by Advent International in January 2019. Integrated drug discovery and development services. Bioduro has completed 1 acquisition, including Molecular Response. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and Medicinal Chemistry.
Company details
BioDuro was founded in 2005 in San Diego, United States, as a contract research, development, and manufacturing entity within the biopharmaceutical sector. Integrated services are delivered for drug discovery, encompassing compound synthesis and optimization across medicinal chemistry, biology, pharmacology, drug metabolism, pharmacokinetics, and safety evaluations. Operations extend to phase II-IV clinical management, data handling, biostatistics, cGMP production of drug products up to phase II, and clinical storage support.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website bioduro.com
- Social LinkedIn
- Acquired by Advent International (Jan 2019)
- InvestorsPPD
& 1 more
- Investments & Acquisitions
- Acquired by
Investors in Bioduro
Bioduro has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include PPD and Advent International.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on multiple sectors | adventinternational.com | Sao Paulo, Brazil | ||
CRO providing diversified clinical development services | 1985 | ppd.com | Wilmington, United States |
Investor details for Bioduro
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Bioduro
15 people are tracked at Bioduro (6 in leadership, 7 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Jim Li | President, Global CMC Solutions - China | Leadership |
Roy Xu | Chief Strategy Officer | Leadership |
Wynn Thai | Sr. Director, Business Development | Leadership |
Ping Zhang | Director, Integrated Service And Alliance, Project Management | Leadership |
Ricardo Inacio | Executive Director | Leadership |
Ajiroghene Thomas | Director Of Business Development | Leadership |
Andrew Li | Director | Board & advisors |
Cathy Yen | Director | Board & advisors |
Kewen Jin | Director | Board & advisors |
Amit Patel | Director | Board & advisors |
Masood Tayebi | Director | Board & advisors |
David Preston | Chairman | Board & advisors |
Michael Miltenberger | Director | Board & advisors |
Alice Lv | SVP, Operations | Team |
Tyler Christian Chiuppi | Quality Assurance Raw Materials | Team |
Complete people profiles for Bioduro
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bioduro
Bioduro has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Molecular Response.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Specializes in biospecimen storage and tumor biobanking services. | molecularresponse.com | San Diego, United States | 2010 | Mar 2018 | β’β’β’β’ |
Complete acquisition details for Bioduro
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Bioduro
4 dated milestones of Bioduro across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Bioduro is founded.
- Exit Acquired by PPD.
- Acquisition Acquires Molecular Response.
- Exit Acquired by Advent International.
Web traffic of Bioduro
The website of Bioduro (bioduro.com) receives about 6.9K visits a month and ranks #3,126,038 among all websites worldwide, #4,117 in Biotechnology and Pharmaceuticals.
- Monthly visits6.9K
▲ 33% vs previous month
- Unique visitors2.4K
per month
- Global rank#3,126,038
among all websites
- Category rank#4,117
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit2.6
- Average visit1 min 14 sec
- DevicesDesktop 30% Β· Mobile 70%
Websites whose visitors overlap most with Bioduro. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cmocro.com | 100% | 21.8K | #1,242,657 | View details | |
sdbn.org | sdbn.org | 92% | #2,959,554 | β | |
| yangzijiang.com | 89% | #559,311 | View details | ||
| wuxiapptec.com | 89% | 107.6K | #296,852 | View details | |
| syngeneintl.com | 86% | 94K | #525,515 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 8 similar websites and full traffic analytics for Bioduro
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Bioduro (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioduro
Complete news archive for Bioduro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bioduro
Bioduro was founded in 2005.
Bioduro is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
BioDuro was founded in 2005 in San Diego, United States, as a contract research, development, and manufacturing entity within the biopharmaceutical sector. Integrated services are delivered for drug discovery, encompassing compound synthesis and optimization across medicinal chemistry, biology, pharmacology, drug metabolism, pharmacokinetics, and safety evaluations. Operations extend to phase II-IV clinical management, data handling, biostatistics, cGMP production of drug products up to phase II, and clinical storage support.
Bioduro has made 1 acquisition, including Molecular Response.
Bioduro has 2 investors. Key investors include PPD, and Advent International.
Yes. Bioduro was acquired by Advent International in January 2019.

